Share on StockTwits
 

GW Pharmaceuticals Plc – American Depositary Shares (NASDAQ:GWPH)‘s stock had its “overweight” rating restated by Piper Jaffray in a research note issued on Friday, Analyst Ratings Network.com reports.

The analysts wrote, “meaningful utility” for seizure patients. The analyst commented that CBD and THC have been reported to benefit individuals with migraine headaches and autism. The analyst wrote that after reviewing Dravet studies, the “finding is consistent with what we have heard from specialists, suggesting the Epidiolex Phase III studies may be overpowered, and thereby substantially improving the probability that the ‘views from the field’ represent a true drug effect.”

Shares of GW Pharmaceuticals Plc – American Depositary Shares (NASDAQ:GWPH) traded up 7.17% during mid-day trading on Friday, hitting $61.85. The stock had a trading volume of 1,443,494 shares. GW Pharmaceuticals Plc – American Depositary Shares has a one year low of $8.46 and a one year high of $65.56. The stock’s 50-day moving average is $46.37 and its 200-day moving average is $27.84. The company’s market cap is $1.069 billion.

GW Pharmaceuticals Plc – American Depositary Shares (NASDAQ:GWPH) last issued its quarterly earnings data on Tuesday, February 4th. The company reported ($0.02) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.34) by $0.32. The company had revenue of $7.49 million for the quarter, compared to the consensus estimate of $11.54 million. The company’s quarterly revenue was up 44.6% on a year-over-year basis. Analysts expect that GW Pharmaceuticals Plc – American Depositary Shares will post $-1.69 EPS for the current fiscal year.

GWPH has been the subject of a number of other recent research reports. Analysts at Leerink Swann initiated coverage on shares of GW Pharmaceuticals Plc – American Depositary Shares in a research note to investors on Tuesday. They set an “outperform” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of GW Pharmaceuticals Plc – American Depositary Shares from $39.00 to $41.00 in a research note to investors on Wednesday, November 20th. They now have a “buy” rating on the stock. Finally, analysts at Cowen and Company raised their price target on shares of GW Pharmaceuticals Plc – American Depositary Shares from $33.00 to $40.00 in a research note to investors on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of $37.00.

GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.